📣 VC round data is live. Check it out!
- Public Comps
- NRGene
NRGene Valuation Multiples
Discover revenue and EBITDA valuation multiples for NRGene and similar public comparables like Vidavo, Biovica International, XIAO-I, Glycorex Transplantation and more.
NRGene Overview
About NRGene
NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.
Founded
N/A
HQ

Employees
N/A
Website
Sectors
Financials (FY)
EV
$6M
Valuation Multiples
Start free trialNRGene Financials
NRGene reported last fiscal year revenue of $3M and negative EBITDA of ($965K).
In the same fiscal year, NRGene generated $2M in gross profit, ($965K) in EBITDA losses, and had net loss of ($2M).
NRGene P&L
In the most recent fiscal year, NRGene reported revenue of $3M and EBITDA of ($965K).
NRGene is unprofitable as of last fiscal year, with gross margin of 61%, EBITDA margin of (30%), and net margin of (47%).
Financial data powered by Morningstar, Inc.
NRGene Stock Performance
NRGene has current market cap of $11M, and enterprise value of $6M.
Market Cap Evolution
NRGene's stock price is $0.81.
NRGene share price decreased by 3.2% in the last 30 days, and by 10.9% in the last year.
NRGene has an EPS (earnings per share) of $-0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6M | $11M | -3.2% | -3.2% | -1.8% | -10.9% | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNRGene Valuation Multiples
NRGene trades at 1.8x EV/Revenue multiple, and (5.8x) EV/EBITDA.
NRGene Financial Valuation Multiples
As of June 2, 2026, NRGene has market cap of $11M and EV of $6M.
NRGene has a P/E ratio of (7.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NRGene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NRGene Margins & Growth Rates
In the most recent fiscal year, NRGene reported gross margin of 61%, EBITDA margin of (30%), and net margin of (47%).
NRGene Margins
NRGene Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
NRGene Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
NRGene Competitors
NRGene competitors include Vidavo, Biovica International, XIAO-I, Glycorex Transplantation, Cipia Vision, VERSES AI, Media Lab, Unith, VSee Health and Ayfie International.
Most NRGene public comparables operate across Artificial Intelligence, Diagnostics & Genomics, Healthcare Software, Vertical AI Applications, AgriTech, B2B SaaS, BioTech, DeepTech, Generative AI and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.8x | - | 9.9x | - | |||
| 2.5x | 1.4x | (0.3x) | (0.4x) | |||
| 4.5x | - | (0.6x) | - | |||
| 2.7x | - | 53.6x | - | |||
| - | - | - | - | |||
| - | - | - | - | |||
| 4.1x | - | 13.3x | - | |||
| 2.4x | - | (3.8x) | - | |||
This data is available for Pro users. Sign up to see all NRGene competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NRGene
| Where is NRGene headquartered? | NRGene is headquartered in Israel. |
| Is NRGene publicly listed? | Yes, NRGene is a public company listed on Tel Aviv Stock Exchange. |
| What is the stock symbol of NRGene? | NRGene trades under NRGN ticker. |
| When did NRGene go public? | NRGene went public in 2021. |
| Who are competitors of NRGene? | NRGene main competitors include Vidavo, Biovica International, XIAO-I, Glycorex Transplantation, Cipia Vision, VERSES AI, Media Lab, Unith, VSee Health, Ayfie International. |
| What is the current market cap of NRGene? | NRGene's current market cap is $11M. |
| What is the current revenue of NRGene? | NRGene's last fiscal year revenue is $3M. |
| What is the current EV/Revenue multiple of NRGene? | Current revenue multiple of NRGene is 1.8x. |
| Is NRGene profitable? | No, NRGene is not profitable. |
| How many companies NRGene has acquired to date? | NRGene hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies NRGene has invested to date? | NRGene hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NRGene
Lists including NRGene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.